SeraCare Life Sciences Inc, Milford, Mass, has launched the Seraseq Fusion RNA Mix v2 and Seraseq FFPE Fusion RNA Reference Material v2. The highly multiplexed mixes include 15 clinically actionable fusion RNA partners. Two formats are offered: both purified nucleic acid (the Fusion RNA Mix) and formalin-fixed, paraffin-embedded tissue slices (FFPE Fusion RNA Reference Material). The updated version of the product includes additional clinically relevant tissue-specific RNA fusions implicated in solid tumors. Newly added fusion partners include SLC45A3-BRAF and TMPRSS2-ERG, both common in prostate cancers, and EGFR-SEPT14, which is common in brain gliomas. These fusion RNAs are detected by commonly available next-generation sequencing-based assays. For more information, visit SeraCare Life Sciences.
